dcsimg

Mary C. DeBartolo

Associate

Related Content

Practices
Education
  • University of Michigan School of Public Health, MPH, Concentration in Health Management & Policy, 2012
  • University of Michigan Law School, JD, cum laude, 2012
  • University of Notre Dame, BA, Economics, cum laude, 2008
Admissions
  • Illinois
Print

Mary focuses on corporate services and transactional and regulatory matters for healthcare providers and companies. In this capacity, she concentrates on acquisitions, divestitures, mergers, private offerings of securities, governance and corporate formation issues, and joint ventures.

Prior to joining McGuireWoods, Mary was an extern for the World Health Organization. While attending law school, she served as article editor for the Michigan Journal of Gender & Law. As an undergraduate, Mary studied in Denmark while completing an International Studies Program.

vCard
T: +1 312 849 8192F: +1 312 920 6160mdebartolo@mcguirewoods.com77 West Wacker Drive
Suite 4100
Chicago, IL 60601-1818
New FDA Guidance on Appeals Processes for Medical Device Denials, May 21, 2013
Indiana Passes Pain Management Clinic Legislation: Four Key Points, May 16, 2013
PhRMA Pushes for Permissive Off-Label Promotion Regime, May 15, 2013
FDA’s Aggressive Inspections Can Deep-Six Pending Filings, May 13, 2013
Bipartisan Bill Gives FDA Control over Certain Compounding Entities: Four Key Points, May 3, 2013
Six Key Points – Proposed Rule on Health Navigators, April 26, 2013
22 Advisory Opinions Issued by the Office of Inspector General (OIG): Six of Interest; Anesthesia ASC Arrangements – Seven Key Concepts; and ASC Anti-Kickback Safe Harbor Issues Nine Key Concepts for 2013 , February 19, 2013
Compounding Pharmacy Oversight Remains a Priority for House Committee, February 7, 2013
FDA Seeks to Raise Metal-on-Metal Hip Implants to Class III and Issues New Safety Recommendations: Potential Retroactive Requirements, January 25, 2013
FDA Introduces New 510(k) Refuse to Accept Policy, January 10, 2013
Caronia: Second Circuit Finds FDA’s Off-Label Promotion Ban Unconstitutional, December 21, 2012
FDA Posts Shorter 510(k) and PMA Approval Times, December 6, 2012
FDA and State Officials to Discuss State and Federal Roles Regarding Compounding Pharmacies, December 4, 2012
Massachusetts Public Health Council Approves “Modest Meals” from Pharmaceutical and Medical Device Manufacturers to Healthcare Providers , November 28, 2012
Amendment to FDA’s Unique Device Identification Rules Shorten Proposed Compliance Deadline, November 27, 2012
Markey Compounding Bill: Key Features of the Proposed Verifying Authority and Legality in Drug Compounding Act of 2012, November 16, 2012
November 7 Comment Deadline for FDA’s Unique Device Identification Rules: Three Key Points, November 6, 2012
Another Attempt at a National Drug Track-and-Trace Proposal: Three Key Points, October 29, 2012
Office of Inspector General to Focus Enforcement on Three Areas of End-Stage Renal Disease Care, October 24, 2012
FDA Finally Concedes It Must Accept More Risk In Order To Spur Innovation, October 5, 2012
Which Medical Devices Are Taxable? : Agencies Have Conflicting Interpretations, September 28, 2012
FDA Layoffs and Extended Approval Times Anticipated if Budget Cuts Trigger Loss of User Fee Funds, September 21, 2012